Literature DB >> 11719444

Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame.

J Yang1, J Luan, Y Yu, C Li, R A DePinho, L Chin, A Richmond.   

Abstract

The molecular and genetic events that contribute to the genesis and progression of cutaneous malignant melanoma are poorly understood, attributable in large part to the different genetic alterations accompanying tumorigenesis. Inhibitor of kinase 4a (INK4a) is often inactivated in families with hereditary melanoma. Loss of INK4a/alternate reading frame (ARF) in mice is associated with increased incidence of other tumors such as lymphoma and fibrosarcoma. However, the incidence of melanoma in INK4a/ARF-deficient mice is very low. Our previous studies have revealed that the CXC chemokine, CXCL1, is overexpressed in human malignant melanoma cells and is linked to transformation of immortalized murine melanocytes. To study the direct role of CXCL1 on the genesis of primary melanoma lesions, transgenic mouse lines were established that express the murine homologue of CXCL1, murine macrophage inflammatory protein 2 (MIP-2), under the transcriptional control of the tyrosinase promoter/enhancer (Tyr-MIP-2) in the mice that were deficient or not deficient for INK4a/ARF. Strong MIP-2 immunoreactivity was associated with pigmented melanocytes in the hyperproliferative hair follicles in the Tyr-MIP-2 transgenic mice, and the level of MIP-2 expression was similar in both INK4a/ARF heterozygous or wild-type mice. After treatment of mice with 7,12-dimethylbenz(a)anthracene, cutaneous melanomas formed in 12% (17/145) of the Tyr-MIP-2 transgene-positive mice, whereas only 2% (3/146) of the Tyr-MIP-2 transgene-negative mice developed melanoma. When melanocytes cultured from MIP-2 transgenic mice null for INK4a/ARF were transplanted into nude mice, melanoma formation occurred in 83% (10/12) of the cases with a latency period of 3 months. However, no melanoma lesions arose in nude mice injected with INK4a/ARF -/- melanocytes, which did not express the MIP-2 transgene. Our results demonstrate that constitutive expression of MIP-2 in INK4a/ARF-deficient melanocytes facilitates formation of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719444

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  NF-κB and STAT1 control CXCL1 and CXCL2 gene transcription.

Authors:  Susan J Burke; Danhong Lu; Tim E Sparer; Thomas Masi; Matthew R Goff; Michael D Karlstad; J Jason Collier
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-11-26       Impact factor: 4.310

3.  Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.

Authors:  T Botton; A Puissant; Y Cheli; T Tomic; S Giuliano; L Fajas; M Deckert; J-P Ortonne; C Bertolotto; S Tartare-Deckert; R Ballotti; S Rocchi
Journal:  Cell Death Differ       Date:  2010-07-02       Impact factor: 15.828

4.  Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth.

Authors:  Jinming Yang; Wei-Hua Pan; Gary A Clawson; Ann Richmond
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 5.  Molecular Pathways: The Necrosome-A Target for Cancer Therapy.

Authors:  Lena Seifert; George Miller
Journal:  Clin Cancer Res       Date:  2016-12-08       Impact factor: 12.531

Review 6.  Role of CXCL1 in tumorigenesis of melanoma.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

7.  CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells.

Authors:  Yukiko Ueda; Yingjun Su; Ann Richmond
Journal:  Melanoma Res       Date:  2007-04       Impact factor: 3.599

8.  INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma.

Authors:  Jinming Yang; Sara Kantrow; Jiqing Sai; Oriana E Hawkins; Mark Boothby; Gregory D Ayers; Eric D Young; Elizabeth G Demicco; Alexander J Lazar; Dina Lev; Ann Richmond
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701

Review 9.  The good and the bad of chemokines/chemokine receptors in melanoma.

Authors:  Ann Richmond; Jinming Yang; Yingjun Su
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-14       Impact factor: 4.693

10.  BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways.

Authors:  Jinming Yang; Katayoun I Amiri; James R Burke; Johannes A Schmid; Ann Richmond
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.